DK0723440T3 - Terapeutiske afgivelsessammensætninger og fremgangsmåder til anvendelse af samme - Google Patents

Terapeutiske afgivelsessammensætninger og fremgangsmåder til anvendelse af samme

Info

Publication number
DK0723440T3
DK0723440T3 DK94931827T DK94931827T DK0723440T3 DK 0723440 T3 DK0723440 T3 DK 0723440T3 DK 94931827 T DK94931827 T DK 94931827T DK 94931827 T DK94931827 T DK 94931827T DK 0723440 T3 DK0723440 T3 DK 0723440T3
Authority
DK
Denmark
Prior art keywords
approximately
c2h4o
methods
c3h6o
integer
Prior art date
Application number
DK94931827T
Other languages
Danish (da)
English (en)
Inventor
Konstantin G Kousoulas
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Application granted granted Critical
Publication of DK0723440T3 publication Critical patent/DK0723440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK94931827T 1993-10-15 1994-10-12 Terapeutiske afgivelsessammensætninger og fremgangsmåder til anvendelse af samme DK0723440T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13827193A 1993-10-15 1993-10-15
PCT/US1994/011594 WO1995010265A1 (fr) 1993-10-15 1994-10-12 Compositions d'apport therapeutique et leurs modes d'utilisation

Publications (1)

Publication Number Publication Date
DK0723440T3 true DK0723440T3 (da) 2003-02-24

Family

ID=22481270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94931827T DK0723440T3 (da) 1993-10-15 1994-10-12 Terapeutiske afgivelsessammensætninger og fremgangsmåder til anvendelse af samme

Country Status (9)

Country Link
EP (1) EP0723440B1 (fr)
JP (1) JP3819422B2 (fr)
KR (1) KR100218140B1 (fr)
AT (1) ATE230260T1 (fr)
AU (1) AU8076494A (fr)
DE (1) DE69431959T2 (fr)
DK (1) DK0723440T3 (fr)
ES (1) ES2189808T3 (fr)
WO (1) WO1995010265A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181937A3 (fr) 1994-08-09 2004-02-04 Cytrx Corporation Vaccin contenant des acides nucléiquées et adjuvant de vaccin
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
WO2001080897A2 (fr) 2000-04-21 2001-11-01 Vical Incorporated Compositions pour l'administration in vivo d'agents therapeutiques derives de polynucleotides et methodes associees
EP1232758A1 (fr) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucléotide formulé en vue d'un transfert intracellulaire amélioré
TR201910060T4 (tr) 2001-12-20 2019-07-22 Merck Sharp & Dohme SYN3 bileşimleri ve yöntemleri.
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
PL3721888T3 (pl) 2013-02-05 2023-04-11 The Board Of Trustees Of The Leland Stanford Junior University Terapie ukierunkowane na cd47 w leczeniu choroby zakaźnej

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3308458A1 (de) * 1983-03-10 1984-09-13 Behringwerke Ag, 3550 Marburg Verfahren zur adjuvierung von vaccinen
IT1191608B (it) * 1985-02-01 1988-03-23 Zambon Spa Composizione farmaceutica e forme farmaceutiche che la contengono
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5221495A (en) * 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
KR100224539B1 (ko) * 1991-03-19 1999-10-15 잭 제이 루체스 개선된 생물학적 활성을 가진 폴리옥시프로필렌/폴리옥시에틸렌 공중합체 조성물
AU3129993A (en) * 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy

Also Published As

Publication number Publication date
AU8076494A (en) 1995-05-04
EP0723440A4 (fr) 1997-06-11
EP0723440A1 (fr) 1996-07-31
ATE230260T1 (de) 2003-01-15
JP3819422B2 (ja) 2006-09-06
WO1995010265A1 (fr) 1995-04-20
EP0723440B1 (fr) 2003-01-02
JPH09503788A (ja) 1997-04-15
DE69431959T2 (de) 2003-11-06
KR960704534A (ko) 1996-10-09
ES2189808T3 (es) 2003-07-16
DE69431959D1 (de) 2003-02-06
KR100218140B1 (ko) 1999-09-01

Similar Documents

Publication Publication Date Title
DK0723440T3 (da) Terapeutiske afgivelsessammensætninger og fremgangsmåder til anvendelse af samme
RU2175337C2 (ru) Полинуклеотидные композиции
EP0677056B1 (fr) Alkylphosphonates et alkylphosphonothioates d'oligonucleotides
AU696635B2 (en) Stabilized oligonucleotides and their use
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
US20050203044A1 (en) Small-mer compositions and methods of use
BR9106729A (pt) Composto,processos para inibir a degradacao por nuclease de compostos e para estabilizar sequencias de nicleotideos ou oligonucleosideos,composicao utilizavel para inibir expressao de genes e processo para inibir expressao de genes em um mamifero necessitando de tal tratamento
MX9406552A (es) Metodo, composiciones y dispositivos para la admi nistracion de polinucleotidos desnudos que codifi can peptidos biologicamente activos.
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
JP2004536103A5 (fr)
HK1048990A1 (en) Novel compounds.
WO2001002424A3 (fr) Inhibiteurs de la protease du virus de l'hepatite c a base d'acide boronique peptide
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
HK1080764A1 (en) Implant for transport and release for pharmacologically active agents as well as a process for producing the same
CA2457034A1 (fr) Compositions ophtalmiques
CA2377290A1 (fr) Utilisation d'un alcane oligomere a haute teneur en fluor en ophtalmologie
HUP0002683A2 (hu) Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek
DK0414607T3 (da) Anti-sense oligonucleotidssekvenser, anti-mRNA mod alpha-TNF; deres fremstilling og anvendelse som lægemiddel samt farmaceutiske præparater med indhold deraf
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
CA2174122A1 (fr) Compositions d'apport therapeutique et leurs modes d'utilisation
EP0733640A4 (fr) Oligonucleotide bicatenaire et agent carcinostatique le contenant en tant que constituant actif
EP0739901A3 (fr) Dérivés d'oligoribonucléotides et leur application comme agents antiviraux
WO2005039480A3 (fr) Desoxyoligonucleotides antisens ache utilises comme agents anti-inflammatoires